Pseudoprogression and Immune-Related Response in Solid Tumors.
Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Victoria L
VL
Chiou
Center for Cancer Research, National Cancer Institute, Bethesda, MD mauricioburotto@yahoo.com.
Mauricio
M
Burotto
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D060890:B7-H1 Antigen / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000074324:Ipilimumab; D008024:Ligands; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D000074324:Ipilimumab; D008024:Ligands; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C000594389:atezolizumab